Published Technical Disclosure Archive

OPCML-based Solutions for Sustainable Agriculture and Environmental Management

Publication ID: 24-11857624_0007_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “OPCML-based Solutions for Sustainable Agriculture and Environmental Management,” Published Technical Disclosure No. 24-11857624_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857624_0007_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,624.

Summary of the Inventive Concept

The present inventive concept leverages the core technology of the original patent to develop novel applications in agriculture, environmental management, and food safety, addressing pressing global challenges.

Background and Problem Solved

The original patent disclosed the role of OPCML in cancer prognosis, theragnosis, treatment, and research. However, the patent's focus on cancer therapy limited its potential applications. The present inventive concept tackles the limitations by exploring OPCML's potential in entirely new industries, including agriculture, environmental management, and food safety.

Detailed Description of the Inventive Concept

The new claims describe systems and methods utilizing OPCML fragments for monitoring and optimizing agricultural crop yields, reducing carbon sequestration in soil, improving water quality in aquatic ecosystems, enhancing the shelf life of perishable food products, and monitoring and detecting biosecurity threats in agricultural settings. These applications capitalize on OPCML's unique properties, offering innovative solutions to pressing environmental and food safety challenges.

Novelty and Inventive Step

The new claims introduce a paradigm shift by applying the core technology of the original patent to unrelated fields, demonstrating a non-obvious and inventive step beyond the original patent's cancer-focused applications.

Alternative Embodiments and Variations

Alternative embodiments could include OPCML-based solutions for precision agriculture, livestock health management, or bioremediation. Variations may involve combining OPCML with other molecules or technologies to enhance its effects or broaden its applications.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the agriculture, environmental management, and food safety industries, with potential markets including precision agriculture, sustainable farming practices, and eco-friendly product development.

CPC Classifications

SectionClassGroup
A A61 A61K39/39558
A A61 A61K31/404
A A61 A61K31/506
A A61 A61K31/517
A A61 A61K31/555
A A61 A61K31/7064
A A61 A61K38/1774
A A61 A61K45/06
C C07 C07K16/28
C C07 C07K16/2863
C C07 C07K16/32
C C12 C12Q1/6886
C C12 C12Q2600/118
C C12 C12Q2600/156
C C12 C12Q2600/158

Field of Art

Biotechnology and molecular biology, with expertise in protein engineering, therapeutic applications, and cross-domain protein manipulation, particularly focused on polypeptide fragment applications in medical and environmental technologies

Person of Ordinary Skill (PHOSITA) Profile

A researcher with advanced degree in biotechnology or molecular biology, familiar with protein fragment engineering, capable of understanding protein structure-function relationships, and experienced in translating therapeutic technologies across different application domains

Obviousness Rationale

A PHOSITA would recognize that the OPCML protein fragment's fundamental structural and functional properties enable its adaptation beyond cancer therapeutics into agricultural and environmental applications. The core molecular mechanism of the OPCML fragment remains consistent across different domains, suggesting predictable and extensible utility. The technical variations represent routine engineering and application translation that would be apparent to a skilled practitioner familiar with protein fragment technologies.

Obvious Combinations & Variations

Source Patent Element
OPCML protein fragment with specific residue ranges (39-219 or 39-310)
PTD Variation
Applying the same protein fragment to crop yield monitoring and agricultural stress detection
Obviousness Reasoning
Known protein engineering techniques allow translating therapeutic protein fragments into sensing and diagnostic applications, representing a predictable extension of the original molecular technology
Source Patent Element
Cancer therapeutic method using protein fragment
PTD Variation
Water quality monitoring and pollutant detection system using identical OPCML fragment
Obviousness Reasoning
Protein fragments with detection capabilities can be readily adapted across biological systems using standard molecular biotechnology techniques
Source Patent Element
Fusion of OPCML fragment with non-OPCML polypeptide
PTD Variation
Combining OPCML fragment with agricultural detection or treatment agents
Obviousness Reasoning
Protein fusion is a standard molecular biology technique for enhancing functional properties, representing an obvious design choice for extending protein utility
Source Patent Element
Method of administering OPCML fragment to biological system
PTD Variation
Administering OPCML fragment to soil, water, or food products for environmental management
Obviousness Reasoning
Protein delivery mechanisms are well-established, and adapting administration techniques across different biological contexts represents routine scientific problem-solving
35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857624, a person having ordinary skill in the art would find the agricultural, environmental, and food safety applications of the OPCML protein fragment to be obvious variations that do not represent a non-obvious inventive step. The disclosed technical variations represent predictable extensions of the original protein fragment technology, utilizing standard molecular engineering techniques to translate a cancer therapeutic approach into alternative domains.

Original Patent Information

Patent NumberUS 11,857,624
TitleCancer therapeutic methods utilizing OPCML fragment
Assignee(s)PAPYRUS THERAPEUTICS, INC.